Immune Genes Protect Cells from Ebola Virus and SARS-CoV-2

A pathway involved in the adaptive immune system, a relative newcomer in the world of pathogen defense, may have a more ancient role in protecting cells from invading viruses.

Written byRachael Moeller Gorman
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: © ISTOCK.COM, 4X-IMAGE

The paper
A. Bruchez et al., “MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses,” Science, 370:241–47, 2020.

Earlier this year, immunologist Adam Lacy-Hulbert of the Benaroya Research Institute in Seattle and his former postdoc Anna Bruchez were writing up their discovery of a previously unknown immune pathway that defends cells against Ebola virus. Then SARS-CoV-2 hit the US. The two suspected that the pathway provided broad antiviral defense, so they decided to test it against the novel coronavirus.

In the Ebola experiments, Lacy-Hulbert, Bruchez, and their colleagues had been using a genetic screen called transposon-mediated gene activation to search for natural antiviral mechanisms within cultured human bone cancer cells. Transposons, mobile genetic elements found throughout the genome, can be added to cells to knock out genes they randomly insert into. The team had integrated a promoter sequence into the transposons so ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After earning a bachelor’s degree in biology and neuroscience from Williams College, Rachael spent two years studying the tiny C. elegans worm as a lab tech at Massachusetts General Hospital/Harvard University. She then returned to school to get a master’s degree in environmental studies from Brown University, and subsequently worked as an intern at Scientific AmericanDiscover magazine, and the Annals of Improbable Research, the originators of the yearly Ig Nobel prizes. She now freelances for both scientific and lay publications, and loves telling the stories behind the science. Find her at rachaelgorman.com or on Instagram @rachaelmoellergorman.

    View Full Profile

Published In

December 2020

Dream Engineers

Manipulating the sleeping brain to understand it

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies